Bempedoic Acid and Ezetimibe
Brand Names: Nexlizet
Methodology & AI Transparency ⓘ
Bempedoic Acid and Ezetimibe Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Bempedoic Acid and Ezetimibe (180 mg/1 / 10 mg/1 Tablet, Film Coated; NDC 72426-818) as a oral-route adenosine triphosphate-citrate lyase inhibitor formulation manufactured/labeled by Esperion Therapeutics, Inc.
- 2 Real-world patient consensus: Real-world cohort score of 78% across 13 de-identified Bempedoic Acid and Ezetimibe entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Most commonly reported Bempedoic Acid and Ezetimibe tolerability events: nausea (8.2%), headache (8%), dizziness (5.5%).
Ask our AI Specialists anything about Bempedoic Acid and Ezetimibe
Bempedoic Acid and Ezetimibe Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Bempedoic Acid and Ezetimibe (180 mg/1 / 10 mg/1 Tablet, Film Coated; NDC 72426-818) as a oral-route adenosine triphosphate-citrate lyase inhibitor formulation manufactured/labeled by Esperion Therapeutics, Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Bempedoic Acid and Ezetimibe exerts selective adenosine triphosphate-citrate lyase inhibitor pharmacodynamic activity across 180 mg/1 / 10 mg/1 Tablet, Film Coated (oral-route route, manufactured/labeled by Esperion Therapeutics, Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 72426-818).
Systemic exposure to Bempedoic Acid and Ezetimibe reflects Oral fraction absorbed ranges from 56% to 68% (Bempedoic Acid and Ezetimibe 180) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of bempedoic acid and ezetimibe, sustaining receptor engagement across a Mean elimination half-life of 10 to 15 hours across adult Bempedoic Acid and Ezetimibe dosing half-life window (oral tmax achieved within 2 to 3 hours following bempedoic acid and ezetimibe ingestion response profile).
Dosing protocols (180 mg/1 / 10 mg/1 Tablet, Film Coated or 180 mg or 10 mg/1 Tablet) balance efficacy (78.00% patient satisfaction across 13 logs) against nausea (8.2% of reports), headache (8% of reports), dizziness (5.5% of reports), with strict avoidance in previous anaphylactoid or exfoliative reaction attributed to bempedoic acid and ezetimibe; clinical scenarios where adenosine triphosphate-citrate lyase inhibitor exposure from bempedoic acid and ezetimibe poses unacceptable risk.
Verify medication reconciliation lists so Bempedoic Acid and Ezetimibe is not inadvertently duplicated with another adenosine triphosphate-citrate lyase inhibitor.
Unstandardized herbal extracts may interact pharmacodynamically with Bempedoic Acid and Ezetimibe maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Bempedoic Acid and Ezetimibe
- Clinical scenarios where adenosine triphosphate-citrate lyase inhibitor exposure from Bempedoic Acid and Ezetimibe poses unacceptable risk
Logged Side-Effect Incidence (13 Reports)
Bempedoic Acid and Ezetimibe Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bempedoic Acid and Ezetimibe)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Factors Associated With Enhanced Low-Density Lipoprotein Cholesterol Lowering: What a 2,321-Participant Study Found Factors including statin absence, female sex, diabetes history, ezetimibe use, and a higher high-sensitivity C-reactive protein level may be useful to identify patients who may have a greater LDL-C reduction with BA. Journal of the American Heart Association • 2022-08-02 • Phase III Randomized Trial | N = 2,321 | 96/100 | PMID 35916348 ↗ |
| New Insights on Long-Term safety and real-world benefits of Bempedoic Acid in Patients With: What a 1,462-Participant Study Found Bempedoic acid was generally well tolerated and demonstrated sustained efficacy with up to 2.5 years of continuous treatment. The American journal of cardiology • 2022-07-01 • Phase III Randomized Trial | N = 1,462 | 96/100 | PMID 35483979 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of Bempedoic Acid in Japanese Patients With high cholesterol This study confirmed the safety and real-world benefits of bempedoic acid after 12 weeks treatment in Japanese patients with high LDL-C who had inadequate response to statins or statin intolerance. Circulation journal : official journal of the Japanese Circulation Society • 2025-07-25 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40159243 ↗ |
| Can This Approach Help? Inside the Latest Research on Characteristics and outcomes of patients with and without statin-associated Patients who reported SAMS, regardless of randomization to bempedoic acid or placebo, had higher rates of discontinuation, higher rates of skeletal muscle. Journal of clinical lipidology • 2025-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39939212 ↗ |
| Can This Approach Help? Inside the Latest Research on Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with high Among patients with high cholesterol, the combination of bempedoic acid, ezetimibe, and atorvastatin significantly lowered LDL-C, allowing more than 90% of patients in this study to reach guideline-recommended LDL-C goals. Atherosclerosis • 2021-03-15 • Randomized Controlled Trial | N = 20 | 88/100 | PMID 33514449 ↗ |
Bempedoic Acid and Ezetimibe Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $13.7964/unit (~$413.89/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 13 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Bempedoic Acid and Ezetimibe Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Bempedoic Acid and Ezetimibe RxNorm Concept ID | RXN-72426818-2250 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $13.7964 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (13 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Bempedoic Acid and Ezetimibe Patient Community, Cohort Filters & Dosage Logs
Cross-verified Bempedoic Acid and Ezetimibe (adenosine triphosphate-citrate lyase inhibitor) monograph synthesizing RxNorm RXN-72426818-2250, openFDA FAERS signals, and $185.00–$453.25 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Bempedoic Acid and Ezetimibe community threads and patient logs by age, biological sex, dosage, and treatment duration.